open-label, multinational trial investigating sofosbuvir plus ribavirin for 12 or 24 week in treatment-naive patient with chronic HCV genotype 1,2,3 or 4 infection and treatment-experienced patients with chronic HCV 2 or 3 infection who are co-infected with HIV-1